Evolus(US:EOLS)2026-01-09 13:34Revenue Projections - Preliminary unaudited net revenue for Q4 2025 is expected to be between $88.6 million and $90.6 million, representing a 12% to 15% increase over Q4 2024[4] - Full-year 2025 net revenue is projected to be between $295.5 million and $297.5 million, reflecting an 11% to 12% growth compared to 2024[4] - The company anticipates 2026 net revenue guidance of $327 million to $337 million, indicating an 11% to 13% growth from 2025[4] - The long-term financial outlook for 2028 is updated to reflect total net revenue between $450 million and $500 million, representing a three-year CAGR of 15% to 19%[4] Profitability - Positive non-GAAP operating income for Q4 2025 is reaffirmed at $5 million to $7 million, marking a significant milestone for the company[4] - The company expects to achieve sustainable annual profitability beginning in 2026[9] Product Contributions - Evolysse injectable hyaluronic acid gels contributed approximately 8% of total revenue for full-year 2025[9] - The anticipated commercial launch of Estyme in Europe is expected to enhance revenue contributions in 2026[9] Strategic Focus - The company is focused on increasing market share and expanding its portfolio internationally, with a disciplined spending approach to drive profitability[3] - Cash and cash equivalents as of December 31, 2025, are reported at $53 million, up from $43.5 million on September 30, 2025, indicating strong sales growth and prudent expense management[9]